These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 25519148)

  • 1. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
    Sasano T; Mabuchi S; Kuroda H; Kawano M; Matsumoto Y; Takahashi R; Hisamatsu T; Sawada K; Hashimoto K; Isobe A; Testa JR; Kimura T
    Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.
    Mabuchi S; Hisamatsu T; Kawase C; Hayashi M; Sawada K; Mimura K; Takahashi K; Takahashi T; Kurachi H; Kimura T
    Clin Cancer Res; 2011 Jul; 17(13):4462-73. PubMed ID: 21622721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary.
    Hisamatsu T; Mabuchi S; Matsumoto Y; Kawano M; Sasano T; Takahashi R; Sawada K; Ito K; Kurachi H; Schilder RJ; Testa JR; Kimura T
    Mol Cancer Ther; 2013 Jul; 12(7):1367-77. PubMed ID: 23615631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
    Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
    PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.
    Mabuchi S; Kawase C; Altomare DA; Morishige K; Sawada K; Hayashi M; Tsujimoto M; Yamoto M; Klein-Szanto AJ; Schilder RJ; Ohmichi M; Testa JR; Kimura T
    Clin Cancer Res; 2009 Sep; 15(17):5404-13. PubMed ID: 19690197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.
    Al Sawah E; Chen X; Marchion DC; Xiong Y; Ramirez IJ; Abbasi F; Bou Zgheib N; Chon HS; Wenham RM; Apte SM; Judson PL; Lancaster JM
    Gynecol Oncol; 2013 Oct; 131(1):207-12. PubMed ID: 23877012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
    Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
    Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
    Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
    BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro.
    Chen MB; Wu XY; Tao GQ; Liu CY; Chen J; Wang LQ; Lu PH
    Int J Cancer; 2012 Dec; 131(11):2487-98. PubMed ID: 22438101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
    Momota H; Nerio E; Holland EC
    Cancer Res; 2005 Aug; 65(16):7429-35. PubMed ID: 16103096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
    Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
    Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition.
    Sun H; Yu T; Li J
    Cancer Lett; 2011 Nov; 310(1):118-28. PubMed ID: 21775054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.
    Mabuchi S; Kawase C; Altomare DA; Morishige K; Hayashi M; Sawada K; Ito K; Terai Y; Nishio Y; Klein-Szanto AJ; Burger RA; Ohmichi M; Testa JR; Kimura T
    Mol Cancer Ther; 2010 Aug; 9(8):2411-22. PubMed ID: 20663925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.
    Cheraghchi-Bashi A; Parker CA; Curry E; Salazar JF; Gungor H; Saleem A; Cunnea P; Rama N; Salinas C; Mills GB; Morris SR; Kumar R; Gabra H; Stronach EA
    Oncotarget; 2015 Dec; 6(39):41736-49. PubMed ID: 26497682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.
    Engel JB; Honig A; Schönhals T; Weidler C; Häusler S; Krockenberger M; Grunewald TG; Dombrowski Y; Rieger L; Dietl J; Wischhusen J
    Eur J Obstet Gynecol Reprod Biol; 2008 Nov; 141(1):64-9. PubMed ID: 18687514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers.
    Engel JB; Schönhals T; Häusler S; Krockenberger M; Schmidt M; Horn E; Köster F; Dietl J; Wischhusen J; Honig A
    Arch Gynecol Obstet; 2011 Mar; 283(3):603-10. PubMed ID: 20405296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J; Zhang L; Zhang X; Xing X
    J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
    Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.